NEW YORK, August 2, 2013 /PRNewswire/ --
Today, Investors' Reports announced new research reports
highlighting Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR),
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Vanda Pharmaceuticals,
Inc. (NASDAQ: VNDA), Illumina Inc. (NASDAQ: ILMN), and Theravance
Inc. (NASDAQ: THRX). Today's readers may access these reports free
of charge - including full price targets, industry analysis and
analyst ratings - via the links below.
Questcor Pharmaceuticals, Inc.
Research Report
On July 30, 2013, Questcor
Pharmaceuticals, Inc. (Questcor) reported its Q2 2013 financial
results, with GAAP net sales of $184.6
million, higher compared to $112.5
million in Q2 2012, primarily due to the expanded usage of
H.P. Acthar Gel in treatment from dermatomyositis,
polymyositis, systemic lupus erythematosus, and rheumatoid
arthritis. The Company also said that the sales growth was due to
increased prescriptions in treatment for nephrotic syndrome and
multiple sclerosis. The Company's GAAP diluted EPS was $1.12 compared to $0.65 in Q2 2012. "Our commercial expansion
effort continues, most recently driven by increasing usage of
Acthar among rheumatologists," said Don M.
Bailey, President and Chief Executive Officer of Questcor.
"This rapid success has encouraged us to accelerate our entry into
pulmonology, where we recently announced a pilot commercialization
effort for respiratory manifestations of symptomatic sarcoidosis, a
labeled indication for Acthar. Additionally, in the second quarter
we acquired the rights to Synacthen, which will further expand our
melanocortin peptide R&D program. This action provides us a
platform for potential further U.S. growth and the initiation of
international commercial activity for Synacthen and potentially for
Acthar." The Full Research Report on Questcor Pharmaceuticals, Inc.
- including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-31/QCOR]
--
BioMarin Pharmaceutical Inc. Research
Report
On July 25, 2013, BioMarin
Pharmaceutical Inc. (BioMarin) reported its Q2 2013 financial
results, with revenue growth of 10.3% YoY to $136.8. GAAP net loss was $21.5 million or $0.16 per diluted share, compared to GAAP net
loss of $32.0 million or $0.27 per diluted share in Q2 2012. "In the
second quarter, we continued to execute on our development goals as
we head into the second half of the year," said Jean-Jacques
Bienaimé, Chief Executive Officer of BioMarin. "We made good
progress in a number of important areas including commercial,
R&D and regulatory." BioMarin reaffirmed its full-year 2013
guidance with total revenue expected in the range of $530 to $555 million. The Full Research Report on
BioMarin Pharmaceutical Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free
of charge at:
[http://www.investorsreports.com/report/2013-07-31/BMRN]
--
Vanda Pharmaceuticals, Inc. Research
Report
On July 29, 2013, Vanda
Pharmaceuticals Inc. (Vanda) announced that its filing for a new
drug application for tasimelteon has been accepted by the US Food
and Drug Administration and granted a priority review
classification. "We are extremely pleased that the FDA has granted
tasimelteon priority review for the treatment of Non-24 in the
totally blind," said Mihael H.
Polymeropoulos, M.D., Vanda's President and Chief Executive
Officer. "The agency's acceptance of the NDA and decision to place
tasimelteon in a category of expedited review are important
milestones for Vanda as we take another step toward our goal of
providing patients with a treatment for Non-24." The Full Research
Report on Vanda Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-07-31/VNDA]
--
Illumina Inc. Research Report
On July 23, 2013, Illumina Inc.
(Illumina) announced the acquisition of Advanced Liquid Logic
(ALL), a leading provider of liquid handling solutions. Illumina
stated that the new, wholly owned subsidiary of Illumina developed
a proprietary "digital microfluidics" technology based on
electrowetting that precisely manipulates small droplets within a
sealed disposable cartridge to perform complex laboratory
protocols. "For our research customers, ALL's technology will
further streamline the industry's simplest NGS workflow, while for
clinical and applied markets, where ease of use and consistency are
especially valued, it will allow us to offer integrated, end-to-end
solutions," said Christian Henry,
Senior Vice President and General Manager of Illumina's Genomic
Solutions business. "ALL brings an impressive IP portfolio in
digital microfluidics and a talented team with a track record of
innovation." The Full Research Report on Illumina Inc. - including
full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-31/ILMN]
--
Theravance Inc. Research Report
On July 25, 2013, Theravance Inc.
(Theravance) reported its Q2 2013 financial results, with revenue
of $1.3 million, slightly lower as
compared to $1.4 million in Q2 2012,
due to the termination of the Company's global collaboration
arrangement with Astellas Pharma Inc. for the development and
commercialization of VIBATIV. Net loss totaled $36.4 million or $0.37 per diluted share, compared with
$37.1 million or $0.42 per diluted share in Q2 2012. Rick E
Winningham, Theravance's Chief Executive Officer, said, "In the
second half of 2013, we anticipate a number of significant events:
the launch of BREO ELLIPTA in the U.S., a potential decision on
RELVAR ELLIPTA in the EU, a PDUFA goal date in December 2013 for ANORO ELLIPTA, results from
Phase 2 studies of TD-9855 and TD-4208 and potential completion of
the separation into two companies. Overall, we believe Theravance
is in a strong position, focusing on its strategy of advancing
medicines in areas of unmet medical need." The Full Research Report
on Theravance Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge
at: [http://www.investorsreports.com/report/2013-07-31/THRX]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by a CFA. However, we are only
human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us
at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Equity News Network. An outsourced research services provider has,
through Chartered Financial Analysts, only reviewed the information
provided by Equity News Network in this article or report according
to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as
to the accuracy or completeness or fitness for a purpose
(investment or otherwise), of the information provided in this
document. This information is not to be construed as personal
financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold
any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may
be occasioned at the time of printing of this document or any
error, mistake or shortcoming. No liability is accepted by Equity
News Network whatsoever for any direct, indirect or consequential
loss arising from the use of this document. Equity News Network
expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Equity News Network
does not (1) guarantee the accuracy, timeliness, completeness or
correct sequencing of the information, or (2) warrant any results
from use of the information. The included information is subject to
change without notice.
InvestorsReports.com
SOURCE Investors' Reports